A Single Centre, Two Treatment, Two Period, Two Sequence, Randomized Crossover Steady-state Relative Bioavailability Study of Naproxen in Two Tablet Formulations Given Twice Daily (PN 400 Tablets Containing 500mg of Naproxen Plus 20mg of Esomeprazole Versus Naprosyn Containing Naproxen 500mg).
Latest Information Update: 05 Feb 2010
At a glance
- Drugs Esomeprazole/naproxen (Primary) ; Naproxen
- Indications Ankylosing spondylitis; Musculoskeletal pain; Osteoarthritis; Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 20 Jan 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 16 Oct 2009 New trial record